neuropsychiatry - Page 1 | CARLAT PUBLISHING

Expert Q&A

The Diagnostic Expansion of ADHD, Part 1

November 1, 2025

C. Thomas Gualtieri, MD

Medical Director, North Carolina Neuropsychiatry Clinics, Chapel Hill and Charlotte, NC. Author of ADD World and the Adderall Explosion (2024).

Dr. Gualtieri has no financial relationships with companies related to this material.

How did we get from “math pills” in 1937 to today’s “ADHD boom”? Dr. Gualtieri traces the surprising history—and overreach—of stimulant use.

Expert Q&A

The Diagnostic Expansion of ADHD, Part 2

November 1, 2025

C. Thomas Gualtieri, MD

Medical Director, North Carolina Neuropsychiatry Clinics, Chapel Hill and Charlotte, NC. Author of ADD World and the Adderall Explosion (2024).

Dr. Gualtieri has no financial relationships with companies related to this material.

Stimulants boost energy, but often mislead. Dr. Gualtieri unpacks misdiagnosis, anxiety, and why careful differential diagnosis matters more than ever.

Clinical Update

Transcranial Direct Current Stimulation

August 1, 2024

Kelvin Quiñones-Laracuente, MD, PhD

Kelvin Quiñones-Laracuente, MD, PhD. Psychiatry resident, NYU Langone Medical Center.

Dr. Quiñones-Laracuente has no financial relationships with companies related to this material.

Your patients may be using it at home (even if they’re not telling you). We look at whether transcranial direct current stimulation (tDCS) works and how it differs from transcranial magnetic stimulation (TMS).

Research Update

Diagnosing Mild Cognitive Impairment: Neuropsych Testing and MoCA Go Head to Head

July 1, 2024

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.

This study compares the MoCA to neuropsychological testing in identifying mild cognitive impairment.

Expert Q&A

Wisdom in Psychiatry

March 1, 2024

Dilip V. Jeste, MD.

Dilip V. Jeste, MD.

Director, Global Research Network on Social Determinants of Health and Exposomics; President-Elect, World Federation for Psychotherapy; Editor-in-Chief, International Psychogeriatrics; Past President, American Psychiatric Association; and coauthor of Wiser (Sounds True; 2020).

Dr. Jeste has no financial relationships with companies related to this material.

Dr. Jeste's research journey challenges stereotypes and explores the science behind mental well-being as we age.

CARLAT WEBINAR

How to Select a Stimulant Formulation

December 6, 2022

Chris Aiken, MD

0.50 CME Credits. Which isomer mix should you choose, and which release mechanism is the best fit for your patient?

Interpreting Assessment Discrepancies from Multiple Sources

October 17, 2022

Joshua Feder, MD and Mara Goverman

In this episode, we will discuss why assessment discrepancies arise, how we can manage them, and what these discrepancies tell us about a patient’s symptoms and response to treatment.

Amphetamine vs Methylphenidate

October 5, 2022

Chris Aiken, MD

0.50 CME Credits. Clinicians should understand how amphetamine and methylphenidate differ in respect to their: risks of psychosis, mania, and substance use, neurotoxic and neuroprotective properties, efficacy and tolerability, and use across the lifespan.

EXPERT Q&A

Assessing and Treating Catatonia in Children and Adolescents

October 1, 2022

Lee Wachtel MD

Lee Wachtel, MD, Medical Director, Neurobehavioral Unit, Kennedy Krieger Institute. Psychiatry Professor, Johns Hopkins School of Medicine. Baltimore, MD.

Dr. Wachtel, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Catatonia is marked by a change from the person’s baseline state with distinct motor, vocal, and behavioral symptoms. Clinicians usually think of a catatonic person as being like a statue—immobile, unresponsive, staring, and with waxy flexibility.

RESEARCH UPDATE

Do White Matter Hyperintensities Predict Memory Loss with Electroconvulsive Therapy?

October 1, 2022

Dax Volle, MD

Dax Volle, MD. Dr. Volle, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

We can continue to recommend ECT to patients with severe white matter hyperintensities and cognitive impairment, as cognition seems to return to baseline following ECT.